Mycrodose Therapeutics' CEO Chad Conner and Nova Mentis Life Science Corp's (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) Marvin Hausman joined Proactive to discuss the new partnership the two groups have formed to to treat neuroinflammatory disorders, such as fragile X syndrome and autism spectrum disorder with psychedelics.
Conner and Hausman say the two groups will be one of the first to partake in a FDA clinical trial that will treat children with psychedelics, with the intention to launch a Phase 2 study 'as soon as possible.'